Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued on Saturday. The firm set a “hold” rating on the stock.

Separately, Cantor Fitzgerald restated a “neutral” rating and set a $3.30 price objective on shares of Aspira Women’s Health in a report on Wednesday, April 10th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ:AWH opened at $3.33 on Friday. The company has a market cap of $41.04 million, a P/E ratio of -0.28 and a beta of 1.61. Aspira Women’s Health has a one year low of $2.31 and a one year high of $6.75. The business’s 50-day simple moving average is $3.58 and its 200 day simple moving average is $4.00.

Aspira Women’s Health (NASDAQ:AWH) last announced its earnings results on Thursday, March 28th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.09. The business had revenue of $2.13 million for the quarter, compared to the consensus estimate of $2.70 million. Aspira Women’s Health had a negative return on equity of 1,099.32% and a negative net margin of 176.74%. Analysts predict that Aspira Women’s Health will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northeast Financial Consultants Inc purchased a new stake in Aspira Women’s Health during the 3rd quarter worth approximately $126,000. Perkins Capital Management Inc. purchased a new stake in Aspira Women’s Health during the 3rd quarter worth approximately $268,000. Quantum Private Wealth LLC increased its holdings in Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after purchasing an additional 21,788 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. grew its position in shares of Aspira Women’s Health by 39.0% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after acquiring an additional 35,177 shares in the last quarter. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.